Kinovate Life Sciences

What Kinovate Life Sciences does

Kinovate Life Sciences, Inc. is a Delaware-incorporated specialty materials company headquartered in Carlsbad, California, and a wholly owned subsidiary of Nitto Denko Corporation (Osaka, Japan, founded 1918). Founded in 2004 as a spin-off from Nitto Denko Technical Corp in Oceanside, California, the company develops and manufactures polymeric solid supports for solid-phase synthesis of therapeutic oligonucleotides, including antisense, RNAi, microRNA, DNA-based, and aptamer drugs at clinical and commercial scales. Its core technology is a proprietary cross-linked polystyrene polymer platform branded as NittoPhase™, which encompasses the original NittoPhase®/UnyLinker™ 350 universal linker (in market for over 20 years), NittoPhase™ HL high-loading support (up to 400 µmol/g), and the forthcoming NittoPhase™ SL (up to 650 µmol/g, scheduled for Q3 2026). Products are manufactured under ISO 9001:2015 guidelines with support from a Nitto Denko production facility in Tohoku, Japan, and the company cites commercial production capability up to 900 mmol for DNA synthesis and 65 mmol for modified RNA synthesis.

The company sells directly to pharmaceutical and biotechnology customers developing and manufacturing therapeutic oligonucleotides, with a secondary segment in diagnostic probe and primer manufacturers. Its go-to-market is quote-based direct sales — customers request quotes via the website, email, or phone, with no e-commerce or reseller channels — augmented by custom project engagements for proprietary linker loading and protocol development. Marketing is concentrated on industry events (TIDES USA, Europe, and Asia), hosted TIDES Talk product launches, downloadable technical documentation on the company website, and LinkedIn presence. Manufacturing integration with Nitto Denko, ISO 9001:2015 certification, and full regulatory documentation support for clinical and commercial programs are central to the value proposition, alongside cited third-party outcomes of up to ~40% reduction in raw materials cost and ~15% reduction in overall synthesis costs relative to alternatives. No public financial disclosures are made, consistent with wholly-owned-subsidiary status.

Name

Kinovate Life Sciences

Legal name

Kinovate Life Sciences, Inc.

Website

https://kinovate.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Kinovate Life Sciences is a wholly owned subsidiary of Nitto Denko Corporation that develops and manufactures proprietary polymeric solid supports (NittoPhase™ platform) for therapeutic oligonucleotide synthesis, selling directly to pharmaceutical and biotech manufacturers worldwide.

Ownership category

akta.pro rank

Product category

Oligonucleotide Synthesis Solid Supports

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Medicinal Chemicals & Botanical Products (2833), Miscellaneous Chemical Products (2890)

akta.pro primary industry

Crystallization, Particle Engineering & Micronization Services (HLAGAHAJ)

Keywords

• Oligonucleotide solid supports
• Polymeric solid phase synthesis
• Therapeutic oligonucleotide manufacturing
• Custom linker loading services
• Pharmaceutical raw materials

Headquarters

HQ city

Oceanside

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Solid Support Product Sales: Kinovate generates revenue through the sale of its NittoPhase™ polymeric solid support product line, including various loading capacities (40 to >400 µmol/g) and linker configurations (deoxy-, ribo-, 2'-methoxy-, 2'-Fluoro-nucleosides, UnyLinker™). Products are sold directly to pharmaceutical and biotech customers involved in therapeutic oligonucleotide development and manufacturing.
2. Custom Project & Custom Loading Services: Revenue derived from custom project engagements including loading customer-supplied proprietary linkers, developing and optimizing loading protocols, and small-scale oligo synthesis evaluation using specialized supports.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Kinovate Life Sciences manufactures and sells high-performance polymeric solid supports (NittoPhase™ platform) used in solid-phase synthesis of therapeutic oligonucleotides including antisense, RNAi, microRNA, and aptamer drugs. Products are sold directly to pharmaceutical and biotechnology manufacturers engaged in clinical and commercial oligonucleotide drug development, with loading capacities ranging from 40 to over 400 µmol/g.

Product overview

Kinovate Life Sciences offers the NittoPhase™ platform, a comprehensive family of polymeric solid supports for therapeutic oligonucleotide synthesis. The platform includes the original NittoPhase®/UnyLinker™ 350 (the flagship universal linker with over 20 years of market presence), NittoPhase™ HL (high-loading support up to 400 µmol/g), and the upcoming NittoPhase™ SL (next-generation support with up to 650 µmol/g for enzymatic ligation applications). All products are manufactured under ISO 9001:2015 guidelines with loading ranges from 40 to 400+ µmol/g, designed for scalability from micromole development to large-scale commercial manufacturing.

Differentiator

Problem solved

Functional benefit

Brands

• NittoPhase™: Family of polymeric solid supports for therapeutic oligonucleotide synthesis, including NittoPhase™ HL (high-loading) and NittoPhase™ SL (standard loading) products.
• NittoPhase™ HL
• NittoPhase™ SL (NPSL)
• UnyLinker™

Products and services

• NittoPhase™ HL (High Loading) High-loading polymeric solid support for therapeutic oligonucleotide synthesis, offering loading capacity up to 400 µmol/g for DNA and RNA synthesis. Delivers superior yields, excellent full-length purity, and significant cost savings through higher synthesis scale per column volume. Proven at commercial production scales up to 900 mmol.
• UnyLinker™ 350 Kinovate's flagship universal linker technology and most recognized product for over 20 years. Built on advanced polymer synthesis technology to serve as a robust solid support for therapeutic oligonucleotide synthesis, delivering industry-leading performance at significantly reduced cost. Available loaded with deoxy-, ribo-, 2'-methoxy-, and 2'-Fluoro-nucleosides at loading ranges from 40 to 400 µmol/g.
• NittoPhase™ SL (Standard Loading) Next-generation solid support engineered with elevated functional density for short-mer oligonucleotide building blocks. Achieves up to 650 µmol/g linker loading density, designed for convergent and fragment-based assembly strategies and enzymatic ligation applications. Slated for Q3 2026 commercial launch.
• Custom Loading & Custom Project Services Custom project engagements including loading customer-supplied proprietary linkers, developing and optimizing loading protocols, and small-scale oligo synthesis evaluation using specialized supports. Fully derivatized and loaded solid supports available to customer specifications, including custom linker loading and non-standard linkers for optimized oligonucleotide synthesis strategies.

Quantifiable outcome

• Up to 40% reduction in raw materials cost and ~15% reduction in overall synthesis costs when using NittoPhase™ HL vs. alternatives, according to third-party testing cited by the company.
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature5 records

Partnerships

One partnership is on record.

• Isis Pharmaceuticals (now Ionis Pharmaceuticals)coreStrategic or Co-development Partner · 8 November 2004Joint development partnership between Kinovate (backed by Nitto Denko Corporation) and Isis Pharmaceuticals for the NittoPhase® solid support product. Isis provided oligonucleotide synthesis and drug development expertise alongside Nitto Denko's polymer synthesis capabilities. Isis incorporated NittoPhase® into its own drug development operations and validated the product's technical and cost performance through rigorous testing.

Scale indicators6 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Glen Research: Glen Research is one of the most established suppliers of solid supports, phosphoramidites, and reagents for DNA and RNA oligonucleotide synthesis. It competes head-to-head with Kinovate's NittoPhase product line in the same product category and serves similar therapeutic and diagnostic oligo manufacturers.
• ChemGenes Corporation: ChemGenes manufactures phosphoramidites, solid supports, and other reagents critical to oligonucleotide synthesis at research and commercial scales. It directly competes with Kinovate's polymeric solid supports as a one-stop reagent supplier to oligo drug developers.
• LGC Biosearch Technologies: LGC Biosearch Technologies supplies custom oligonucleotide synthesis services and reagents, including solid supports, for therapeutic and diagnostic applications. It overlaps with Kinovate in both reagent supply and oligo manufacturing-adjacent capabilities serving similar customer profiles.
• TriLink BioTechnologies: TriLink BioTechnologies (part of Maravai LifeSciences) manufactures modified nucleic acid products, including custom oligonucleotide synthesis, mRNA, and related reagents used in therapeutic development. It is comparable to Kinovate as a manufacturer serving therapeutic oligo developers, though with a broader portfolio beyond solid supports.
• BioAutomation: BioAutomation supplies oligonucleotide synthesis reagents including solid supports, amidites, and ancillary products used in DNA/RNA synthesis. It directly competes with Kinovate's NittoPhase platform for the same therapeutic and research oligo customers.

Broad incumbents

• Eurofins Genomics: Eurofins Genomics is a large-scale provider of oligonucleotide synthesis services and reagents for research, diagnostic, and applied markets. While its core business is custom oligo services, its reagent and consumables portfolio overlaps with Kinovate's solid support offerings.
• Cytiva (formerly GE Healthcare Life Sciences): Cytiva supplies bioprocessing and oligo manufacturing equipment including ÄKTA Oligopilot and OligoProcess synthesizers that Kinovate's NittoPhase supports are explicitly designed to integrate with. Both companies serve oligo therapeutic manufacturers along the same production workflows.
• Thermo Fisher Scientific (Applied Biosystems): Thermo Fisher Scientific, through its Applied Biosystems brand, is a dominant supplier of oligonucleotide synthesis instruments, reagents, and consumables used across research, diagnostic, and therapeutic workflows. It competes broadly with Kinovate in the oligo synthesis supply chain, though at much greater scale and portfolio breadth.
• MilliporeSigma (Sigma-Aldrich): MilliporeSigma supplies an extensive portfolio of chemical reagents and life science products, including materials used in oligonucleotide synthesis. It is a broader incumbent serving overlapping chemistry needs across pharmaceutical and biotech customers.
• Agilent Technologies: Agilent provides analytical instruments, reagents, and services for nucleic acid analysis and synthesis, including oligonucleotide characterization. While not a direct solid support competitor, Agilent serves many of the same therapeutic oligo customers and operates in the adjacent nucleic acid workflow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/kinovate-life-sciences-inc

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kinovate Life Sciences